sdi-118
Small moleculeexperimental
Clinical trial activity
6 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 14, 2019 (NCT05486195)
Timeline
Indications
Mechanism of action
SV2A agonist
Chemistry & pharmacology
Loading structure…
SMILES
O=C1C[C@H](c2cc(F)c(F)c(F)c2)CN1Cn1ncnc1Cl- Mol. weight
- 330.7 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314929 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06278766 | Phase 1 | Feb 21, 2024 | AbbVie |
| NCT05771428 | Phase 2 | Apr 27, 2023 | AbbVie |
| NCT05686980 | Phase 1 | Jan 17, 2023 | AbbVie |
| NCT05199142 | Phase 1 | Sep 23, 2021 | Syndesi |
| NCT05212116 | Phase 1 | Sep 16, 2021 | P1vital Limited, Syndesi, University of Oxford |
| NCT05486195 | Phase 1 | Mar 14, 2019 | AbbVie, Katholieke Universiteit Leuven, Syndesi |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 4 | 4 | 2 | 2019 |
| Syndesi | For profit | 3 | 2 | 1 | 2019 |
| Katholieke Universiteit Leuven | Academic/Hospital | 1 | 0 | 1 | 2019 |
| P1vital Limited | For profit | 1 | 0 | 1 | 2021 |
| University of Oxford | Academic/Hospital | 1 | 0 | 1 | 2021 |
5 organizations
Page 1 / 1